Arbutus Biopharma Corpora... (ABUS)
Arbutus Biopharma Corporation (ABUS) Stock Price, Analysis & Data
No hay datos disponibles
| Precio de compra | 3.68 |
| Capitalización de mercado | 985.28M |
| Ingresos (TTM) | 181.72M |
| Beneficio neto (TTM) | 153.05M |
| Beta | 0.60 |
| EPS (TTM) | 0.79 |
| Ratio PER (TTM) | 6.3 |
| Adelante PE | -30.13 |
| P/B (TTM) | 3.80 |
| P/S (TTM) | 5.42 |
| Earnings Date | Nov 16, 2026 |
| Precio de venta | 4.99 |
| Volumen | 3,362,368 |
| Volumen medio (20D) | 2,008,095 |
| Abierto | 4.83 |
| Anterior Cerrar | 4.84 |
| Rango del día | 4.83 - 5.17 |
| Rango de 52 semanas | 3.44 - 5.38 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de ABUS
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1...
Desempeño financiero
En 2025, los ingresos de Arbutus Biopharma fueron 14.08M, un aumento de 128.21% en comparación con 6.17M del año anterior. Las ganancias fueron -33.5M, una disminución de -52.09%.
Estados financierosSorpresa de resultados
Los analistas proyectan ingresos de ... Actualizar
3 semanas hace · Simply Wall St.
Pfizer (PFE) Faces Expanded Vaccine Lawsuits On A Fair Value Narrative That Still Sees UpsidePfizer (PFE) is back in focus after Arbutus Biopharma and Genevant Sciences expanded their patent litigation over mRNA lipid nanoparticle technology, adding new international cases that raise legal an...
